DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

流感病毒疫苗小分子双佐剂体系的研制

• 批准号: 10935796
• 负责人: JENNIFER LAPEK
• 金额: $ 247.18万
• 依托单位: SCRIPPS INSTITUTION OF OCEANOGRAPHY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2028-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935796
• 关键词: Adjuvant; Agonist; Animal Model; Animals; Chronic Disease; Clinical Trials; Communicable Diseases; Contractor; Development; Drug Kinetics; Elderly; Fluzone; Formulation; Frequencies; Human; Immune; Immunization; Individual; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B Virus; Modeling; Mus; Patients; Prevention; Route; Structure-Activity Relationship; Support Contracts; System; TLR4 gene; TLR7 gene; Toxicology; Vaccine Adjuvant; Vaccines; aged; cross immunity; dosage; efficacy study; immunogenicity; improved; influenza virus strain; influenza virus vaccine; influenzavirus; manufacture; novel vaccines; protective efficacy; safety study; seasonal influenza; small molecule

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.

“预防胜于治疗”是传染病疫苗背后的动机。目前的流感疫苗需要帮助，因为它们只在短时间内有效，特别是对老年人和慢性病患者。此外，每年必须研制新的疫苗，以预防新的流感病毒株。因此，对开发新的免疫增强佐剂以改进现有流感疫苗有很大的需求。我们的合同支持开发一种新的疫苗佐剂Fos47，它可以提高疫苗的耐久性和动物模型的交叉保护。将在流感病毒攻击模型中评估疫苗佐剂Fos47的保护功效，以确定最佳剂量、免疫途径和免疫频率。疫苗佐剂将大规模制备，开始人体临床试验。